[Chemotherapeutic combinations of mutually potentializing drugs. 1-Application to the treatment of breast cancers].
27 patients suffering from disseminated carcinoma of the breast with at least two visceral metastases, and two had become resistant to conventional chemotherpy and hormones, received a combination of, in the present trial, vincristine followed by cyclophosphamide with 5-fluoro-uracil. Chemotherapy was administered intermittently: each cycle of treatment lasted 6 days and was followed by a period without treatment of 25 days. Haematological tolerance was satisfactory. No serious incidents occurred during two years use of the combination. 20 out of 27 patients showed objective tumour regression of more than 50 p.cent lasting for more than 6 months, whilst 9 showed apparent complete regression of the malignant lesions. There was one complete failure. Chemotherapy was continued in all cases after regression of the neoplastic process was obtained.
D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009461:Neurologic Manifestations; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011034:Podophyllotoxin / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D014750:Vincristine; D003520:Cyclophosphamide; D011034:Podophyllotoxin; D005472:Fluorouracil; D008727:Methotrexate
Combinaisons chimiothérapiques de drogues se potentialisant. I. Application au traitement des cancers du sein